|
| |
Center of Molecular ImmunologyThe Center of Molecular Immunology’s main mission is to obtain and produce new biopharmaceutical products used in the treatment of cancer and other chronic non transmissible diseases and introduce them in the Cuban Public Healthcare System. Make the scientific and productive activities economically sustainable and contribute to the economy of the country.
On December 5th, 1994 on the west side of Havana the Center of Molecular Immunology is inaugurated. For the design and construction of the Center of Molecular Immunology the current Good Manufacturing Practices Guidelines adopted by Cuba and recommended by the World Health Organization were used particularly those adopted also by the countries member of the European Community.
The new building is basically two floor facility of over 15,000 square meters.
In the Center of Molecular Immunology work approximately 400 employees, most of them scientists and engineers. These personnel are administratively organized in three main areas: Research and Development, Production and Quality Assurance.
Today CIM produces Biopharmaceutical products, such as: an anti CD3 monoclonal antibody for the treatment of patients with organ transplant rejection, human recombinant Erythropoietin for the treatment of anemia, granulocyte Colony Stimulating Factor for the treatment of neutropenia, a humanized monoclonal antibody that recognizes the epidermal growth factor receptor for cancer treatment as well as other monoclonal antibodies for tumor imaging.
| Contact Details: |
| Calle 15 esq. 216, Siboney, Playa |
| Ciudad de la Habana |
| |
| |
| Cuba |
| Tel: | 53 (7) 2714335 |
| Fax: | 53 (7) 2720644 |
| Email: | lage@ict.cim.sld.cu |
| WWW: | www.cim.sld.cu/
|
| |
Recent Publications by Center of Molecular Immunology: |  |
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody.
N-Glycolylated (NeuGc) gangliosides are tumor-specific antigens and as... | 21st October, 2009
| Center of Molecular Immunology, Havana, Cuba.
| Mol Immunol. 2009 Oct;46(16):3466-75. Epub 2009 Sep 12.
DOI Direct Link |
Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Overexpression of the epidermal growth factor (EGF) receptor (EGFR) in... | 26th September, 2009
| Center of Molecular Immunology, Havana, Cuba.
| Cancer Res. 2009 Jul 15;69(14):5851-9. Epub 2009 Jul 7.
DOI Direct Link |
Spatial analysis of breast and cervical cancer incidence in small geographical areas in Cuba, 1999-2003.
According to the data from the National Cancer Registry, breast and... | 16th September, 2009
| Section of Data Management and Biostatistics, Clinical Trials Department,
| Eur J Cancer Prev. 2009 Sep;18(5):395-403.
DOI Direct Link |
Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease.
The relationship between autoantibodies (autoAbs) to oxidized LDL (oxLDL)... | 5th September, 2009
| Center of Molecular Immunology, Havana, Cuba.
| Hum Antibodies. 2009;18(3):109-17.
DOI Direct Link |
Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine.
Cancer vaccines efficacy may improve inducing a rapid and persistent... | 19th June, 2009
| Experimental Immunotherapy Department, Center of Molecular Immunology, 216
| Vaccine. 2009 Apr 6;27(16):2230-9. Epub 2009 Feb 13.
DOI Direct Link |
→View more Center of Molecular Immunology research publications. |
Press Releases on Center of Molecular Immunology:
|
 |
| YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA |
23rd November, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
|
| YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING |
18th November, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
|
| YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING |
17th November, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Nov. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
|
| YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS |
11th November, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Nov. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
|
| YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 |
2nd November, 2009 |
YM BioSciences Inc. |
- Follow-On Results from a Randomized Phase IIb Head & Neck Trial
Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated
Toxicities -
MISSISSAUGA, ON, Nov. 2
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 18 individuals from Center of Molecular Immunology using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 271 times since April 2007, the link to the organisation's website has been followed 51 times Search for more companies in Ciudad de la Habana Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Center of Molecular Immunology |
